[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Hasebe T, Tamura N, Iwasaki M, Okada N, Akashi-Tanaka S, Hojo T, Shimizu C, Adachi M, Fujiwara Y, Shibata T, Sasajima Y, Tsuda H, Kinoshita T: Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy. Mod Pathol; 2010 Apr;23(4):581-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy.
  • The purpose of this study was to confirm that the grades of lymph vessel tumor emboli in biopsy specimens obtained before neoadjuvant therapy and in the surgical specimens obtained after neoadjuvant therapy according to the grading system we devised are significant histological outcome predictor for invasive ductal carcinoma (IDC) patients who received neoadjuvant therapy.
  • The lymph vessel tumor embolus grades in the biopsy specimens and in the surgical specimens were significantly associated with the increases in mean number of nodal metastases.
  • Multivariate analyses with well-known prognostic factors and p53 expression in tumor-stromal fibroblasts clearly showed that the lymph vessel tumor embolus grade based on the biopsy specimens and based on the surgical specimens significantly increased the hazard rates for tumor recurrence and tumor-related death in all the IDC patients as a whole, in the IDC patients who did not have nodal metastasis, and in the IDC patients who had nodal metastasis, and the outcome-predictive power of the lymph vessel tumor embolus grades based on the surgical specimens was superior to that of the lymph vessel tumor embolus grades based on the biopsy specimens.
  • The grades in the grading system for lymph vessel tumor emboli were significantly associated with nodal metastasis, and the histological grading system is an excellent system for accurately predicting the outcome of patients with IDC of the breast who have received neoadjuvant therapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymphatic Metastasis / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoadjuvant Therapy. Prognosis. Proportional Hazards Models

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118911.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Tamura N, Hasebe T, Okada N, Houjoh T, Akashi-Tanaka S, Shimizu C, Shibata T, Sasajima Y, Iwasaki M, Kinoshita T: Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer Sci; 2009 Oct;100(10):1823-33
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy.
  • The present study investigated fibrotic foci (FFs), the grading system for lymph vessel tumor emboli (LVTEs), and the histological characteristics of nodal metastatic tumors that were significantly associated with the outcomes of 115 patients with invasive ductal carcinoma (IDC) who had received neoadjuvant chemotherapy.
  • We compared the outcome predictive power of FFs, the grading system for LVTEs, and the histological characteristics of metastatic tumors in lymph nodes with the well-known clinicopathological characteristics of tumor recurrence and tumor-related death in multivariate analyses.
  • The presence of FFs, as assessed by a biopsy performed before neoadjuvant chemotherapy, significantly increased the hazard rates (HRs) for tumor-related death in all the cases and in cases with nodal metastasis.
  • The grading system for LVTEs, which was assessed using surgical specimens obtained after neoadjuvant chemotherapy, was significantly associated with increasing hazard rates (HRs) for tumor recurrence and tumor-related death in all the cases and in cases with nodal metastasis.
  • Moderate to severe stroma in nodal metastatic tumors and five or more mitotic figures in nodal metastatic tumors were significantly associated with elevated HRs for tumor recurrence and tumor-related death among all the cases.
  • These results indicated that FFs, the grading system for LVTEs, and the histological characteristics of tumor cells in lymph nodes play important roles in predicting the tumor progression of IDCs of the breast in patients treated with neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Vessels / pathology. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604245.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Stefansson IM, Salvesen HB, Akslen LA: Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res; 2006 Mar 15;66(6):3303-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiogenesis is essential for tumor growth, invasion, and metastatic spread.
  • Whereas microvessel density (MVD) has been widely used as a measure of tumor-associated angiogenesis, we now wanted to examine the significance of other angiogenic markers, especially vascular proliferation (by Ki-67/factor VIII staining) and the degree of pericyte coverage [by alpha-smooth muscle actin (alpha-SMA)/factor VIII staining], in a large and population-based series of endometrial carcinoma with complete follow-up.
  • Due to limited information on the role of lymphangiogenesis in these tumors, lymphatic vessel density (LVD) by LYVE-1 staining was also determined, as well as selected angiogenic factors [vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-D and basic fibroblast growth factor (bFGF)], which could possibly be related to vascular proliferation and lymphangiogenesis.
  • The information on angiogenic phenotype was related to clinicopathologic features and disease progress.
  • Median vascular proliferation, as estimated by vascular proliferation index (VPI), was 3.9% and high VPI was associated with features of aggressive tumors and decreased survival.
  • Presence of pericyte coverage, as estimated by the alpha-SMA index (SMAI), was 35% and low SMAI was significantly associated with vascular invasion by tumor cells and impaired prognosis.
  • Peritumoral lymphatic vessels (LVD-pt) were found in 39.5% of the cases and high LVD-pt was significantly associated with aggressive tumor features and decreased survival.
  • In multivariate survival analysis, only the extent of vascular proliferation had independent prognostic effect, in addition to well-known clinicopathologic factors, whereas MVD did not have significant prognostic value.
  • [MeSH-minor] Actins / metabolism. Cell Growth Processes / physiology. Disease Progression. Female. Fibroblast Growth Factor 2 / biosynthesis. Humans. Lymphatic Vessels / pathology. Multivariate Analysis. Neoplasm Staging. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Survival Rate. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540684.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


Advertisement
4. Azzali G: Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate. Am J Pathol; 2007 Jan;170(1):334-46
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate.
  • The distribution and fine structure of the tumor-associated absorbing lymphatic vessel in the tumor mass of prostate adenocarcinoma and of seminal vesicle metastasis in transgenic mice was studied for the purpose of understanding the modality of tumor cell transendothelial passage from the extravasal matrix into the lymphatic vessel.
  • In the tumor mass, two main cell populations were identified: stromal tumor cells and the invasive phenotype tumor (IPT) cells, having characteristics such as a highly electron-dense matrix rich in small granules lacking a dense core and massed nuclear chromatin, which is positive to immunostaining with anti-SV40 large T antigen antibody.
  • Based on the ultrastructural pictures of different moments of the IPT cell transendothelial passage by ultrathin serial sections of the tumor-associated absorbing lymphatic vessel, the manner of its transendothelial passage through the intraendothelial channel, without involving intercellular contacts, was demonstrated.
  • The presence of IPT cells in the parenchyma of satellite lymph node highlights its significant role in metastatic diffusion.
  • The intraendothelial channel is the reply to the lack of knowledge regarding the intravasation of the tumor cell into the lymphatic circulation.
  • The lymphatic endothelium would organize this channel on the basis of tumor cell-endothelial cell-extravasal matrix molecular interactions, which are as yet unidentified.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Movement. Lymphatic Metastasis / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Animals. Antigens, Polyomavirus Transforming / metabolism. Cell Communication. Cytoplasmic Granules / pathology. Endothelium, Lymphatic / pathology. Endothelium, Lymphatic / ultrastructure. Lymph Nodes / pathology. Male. Mice. Mice, Inbred C57BL. Mice, Nude. Mice, Transgenic. Microscopy, Electron. Seminal Vesicles / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 May 30;276(5317):1423-5 [9162011.001]
  • [Cites] Nat Biotechnol. 1997 Aug;15(8):778-83 [9255794.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 [9435229.001]
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Microvasc Res. 1999 Jan;57(1):30-43 [9882560.001]
  • [Cites] J Exp Med. 1999 Feb 1;189(3):451-60 [9927507.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):385-94 [10027397.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):309-13 [10390013.001]
  • [Cites] Microsc Res Tech. 2001 Oct 15;55(2):70-80 [11596152.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9 Suppl):1S-4S [11599891.001]
  • [Cites] Eur J Biochem. 2001 Nov;268(21):5530-40 [11683876.001]
  • [Cites] Pathol Oncol Res. 2001;7(3):217-30 [11692150.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 7;93(21):1638-43 [11698568.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):773-83 [11937485.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):434-40 [11950918.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):713-8 [12235205.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;979:120-30 [12543722.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):40-7 [12544520.001]
  • [Cites] Trends Cardiovasc Med. 2003 Jan;13(1):1-7 [12554094.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1920-6 [12702584.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Pathol. 2003 Jun;200(2):195-206 [12754740.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3172-9 [12789293.001]
  • [Cites] FASEB J. 2003 Jul;17(10):1292-4 [12738812.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):413-23 [12872364.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):716-9 [12874070.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):204-11 [12970722.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] J Cell Biol. 2003 Oct 27;163(2):209-13 [14581448.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):47-50 [14654901.001]
  • [Cites] Int Rev Cytol. 2003;230:41-87 [14692681.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5137-44 [15297417.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):333-45 [15488757.001]
  • [Cites] Experientia. 1975 May 15;31(5):590-1 [1140264.001]
  • [Cites] Experientia. 1976 Mar 15;32(3):377-8 [1253918.001]
  • [Cites] Experientia. 1977 Jul 15;33(7):837-43 [330195.001]
  • [Cites] Can Med Assoc J. 1983 May 15;128(10):1164-7 [6340812.001]
  • [Cites] Cancer Metastasis Rev. 1983;2(3):307-17 [6367969.001]
  • [Cites] Arch Histol Jpn. 1985 Jul;48(3):255-68 [4062499.001]
  • [Cites] Lymphology. 1990 Mar;23(1):4-14 [2191172.001]
  • [Cites] Acta Biomed Ateneo Parmense. 1990;61(1-2):41-56 [1722066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Cell. 1999 Sep 17;98(6):769-78 [10499794.001]
  • [Cites] Anat Anz. 1951;97(Suppl.):89-92 [14915071.001]
  • [Cites] J Cell Biol. 1963 Apr;17:208-12 [13986422.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):539-49 [15563315.001]
  • [Cites] J Urol. 2005 Jan;173(1):10-20 [15592017.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):121-7 [15710325.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1089-99 [15809353.001]
  • [Cites] Ultrastruct Pathol. 2005 Sep-Oct;29(5):367-75 [16257863.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9789-98 [16267000.001]
  • [Cites] J Pathol. 2000 Feb;190(3):310-29 [10685065.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4324-7 [10969769.001]
  • [Cites] Histochem Cell Biol. 2000 Nov;114(5):373-85 [11151407.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):672-82 [11179212.001]
  • [Cites] Nat Med. 2001 Feb;7(2):186-91 [11175849.001]
  • [Cites] Nat Med. 2001 Feb;7(2):192-8 [11175850.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):3-12 [14984763.001]
  • [Cites] Novartis Found Symp. 2004;256:112-31; discussion 132-6, 259-69 [15027486.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):254-8 [15050959.001]
  • [Cites] J Urol. 2004 Jul;172(1):103-7 [15201747.001]
  • [Cites] Pulm Pharmacol Ther. 2006;19(1):51-60 [16286238.001]
  • [Cites] Microvasc Res. 2006 Jul-Sep;72(1-2):74-85 [16730031.001]
  • [Cites] Nat Med. 2001 Feb;7(2):199-205 [11175851.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):317-21 [11377291.001]
  • [Cites] Microsc Res Tech. 2001 Oct 15;55(2):61-9 [11596151.001]
  • [Cites] EXS. 1997;79:65-112 [9002221.001]
  • (PMID = 17200205.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming
  • [Other-IDs] NLM/ PMC1762681
  •  go-up   go-down


5. Oki E, Kakeji Y, Zhao Y, Yoshida R, Ando K, Masuda T, Ohgaki K, Morita M, Maehara Y: Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol; 2009 Sep;16(9):2510-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Data and tumor specimens were collected from 240 gastric cancer patients from 1993 to 2002.
  • RESULTS: This analysis identified 22 MSI-H (9.4%), 25 MSI-L (10.7%), and 193 MSS (79.9%) tumors.
  • Gastric cancer with MSI-H tended to have increased likelihood to show higher age, antral location of the tumor, and lymph vessel involvement (P < 0.05).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Microsatellite Instability. Neoplasm Recurrence, Local / genetics. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565284.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Hasebe T, Yamauchi C, Iwasaki M, Ishii G, Wada N, Imoto S: Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol; 2008 Mar;39(3):427-36
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast.
  • There are no suitable histologic diagnostic clues for determining the true biological malignancy of invasive ductal carcinomas associated with lymph vessel tumor emboli.
  • The purpose of this study was to devise a grading system for lymph vessel tumor emboli in invasive ductal carcinomas that would allow accurate prediction of the outcome of invasive ductal carcinoma patients with lymph vessel invasion.
  • We classified 393 invasive ductal carcinomas into the following 4 grades according to the number of mitotic and apoptotic figures in tumor cells in lymph vessels at 1 high-power field: grade 0, no lymph vessel invasion; grade 1, absence of mitotic and apoptotic figures, presence of any number of mitotic figures and absence of apoptotic figures, or absence of mitotic figures and presence of any number of apoptotic figures; grade 2, 1 to 4 mitotic figures and 1 or more of apoptotic figures, or 1 or more of mitotic figures and 1 to 6 apoptotic figures; and grade 3, more than 4 mitotic figures and more than 6 apoptotic figures.
  • The mortality rate increased with the grade, and the mortality rate of patients with grade 3 lymph vessel tumor emboli was more than 70%.
  • Multivariate analyses with well-known prognostic factors demonstrated that grade 3 lymph vessel tumor emboli significantly increased the hazard rates for tumor recurrence, and tumor death independent of adjuvant therapy status, nodal status, or invasive tumor size.
  • The grading system for lymph vessel tumor emboli is the best histologic grading system for accurately predicting the outcome of patients with invasive ductal carcinoma of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Diagnostic Techniques and Procedures. Lymphatic Vessels / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis / physiology. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Middle Aged. Mitosis / physiology. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261627.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Yamauchi C, Hasebe T, Iwasaki M, Imoto S, Wada N, Fukayama M, Ochiai A: Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol; 2007 Feb;38(2):247-59
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance.
  • Lymph vessel tumor emboli (LVTEs) within tumors are difficult to distinguish from stroma-invasive tumor foci.
  • We first attempted to identify LVTE in the stroma-invasive tumor area (intratumor area), the advance area, and the nontumor area by HE staining alone, and then LVTE identified by HE staining was confirmed by D2-40 staining.
  • Although D2-40 staining detected larger numbers of LVTE than HE staining in all tumor areas, the highest positive predictive value of LVTE was observed in the intratumor area, and the next was in the advance area, and then the nontumor area, and significant correlations were found between the numbers of LVTE stained by HE and D2-40 in the same tumor areas.
  • LVTE identified by HE staining or D2-40 staining in the intratumor area or nontumor area significantly increased the risk for tumor recurrence or death of patients with IDC, independent of hormone receptor status or nodal status.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Vessels / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / analysis. Antibodies, Monoclonal, Murine-Derived. Eosine Yellowish-(YS). Female. Hematoxylin. Histocytochemistry. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Predictive Value of Tests. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Survival Analysis

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056095.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / monoclonal antibody D2-40; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


8. Hasebe T, Okada N, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Tsuda H, Kinoshita T: Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast. Hum Pathol; 2010 May;41(5):706-15
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast.
  • The purpose of this study was to confirm that the grading system for lymph vessel tumor emboli is a significant histologic outcome predictor for patients with invasive ductal carcinoma.
  • We classified all invasive ductal carcinomas according to the grading system for lymph vessel tumor emboli we devised, and performed multivariate analyses with well-known prognostic factors.
  • Of 1042 carcinomas, 666, 250, 97, and 29 were classified according to the grading system for lymph vessel tumor emboli as grade 0 (no lymph vessel invasion), grade 1, grade 2, and grade 3, respectively.
  • Multivariate analyses demonstrated that having a grade 2 or grade 3 carcinoma significantly increased the hazard rates for tumor recurrence and tumor-related death in the patients as a whole as well as in both the group of patients with nodal metastasis and the group without nodal metastasis.
  • The grading system for lymph vessel tumor emboli is an excellent histologic grading system for predicting the outcome of patients with invasive ductal carcinoma of the breast.
  • [MeSH-minor] Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Lymphatic Vessels / pathology. Multivariate Analysis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20060154.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Azzali G: On the transendothelial passage of tumor cell from extravasal matrix into the lumen of absorbing lymphatic vessel. Microvasc Res; 2006 Jul-Sep;72(1-2):74-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the transendothelial passage of tumor cell from extravasal matrix into the lumen of absorbing lymphatic vessel.
  • The aim of the research is the study of ultrastructural characteristics of the absorbing lymphatic vessel and of tumor cell passage through the endothelial lymphatic wall in (a) subcutaneous xenografts of T84 colon adenocarcinoma and B16 melanoma cell lines in nude mice and (b) human colorectal cancer.
  • It was found that the tumor-associated absorbing lymphatic (TAAL) vessel has the same ultrastructural characteristics as the absorbing lymphatic vessel in normal organs, and it is provided with an endothelial wall wholly lacking a continuous basement membrane, pores, fenestrations, and open junctions.
  • The TAAL vessel is always missing in the studied tumor masses as far as the central stroma is concerned, whereas it is always present in the peripheral area of the tumor and in the peritumoral connective tissue.
  • The factors of extravasal matrix that play an active role in migration process of invasive phenotype tumor (IPT) cell after its detachment from tumor mass, as well as the role of cytoplasmic protrusions (pseudopod-like) in lymphatic recognition, were considered.
  • For the first time, this study demonstrated the transendothelial passage of IPT cell inside the TAAL vessel lumen, which takes place by means of the intraendothelial channel (approximately 1.8-2.1 mum in diameter and 6.8-7.2 microm in length).
  • This channel is to be considered a transient morphological entity organized by TAAL vessel endothelium by means of still unidentified molecular mechanisms.
  • Therefore, it appears to be ascertained that the intraendothelial channel represents a step forward in the knowledge of the drainage into lymphatic circulation of interstitial fluid and the answer to the lack of knowledge expressed till today by researchers concerning the modality of passage of the tumor cell through the endothelial wall of the TAAL vessel.
  • [MeSH-major] Lymphatic Vessels / pathology. Microcirculation
  • [MeSH-minor] Animals. Cell Line, Tumor. Diffusion. Endothelium, Vascular / metabolism. Humans. Imaging, Three-Dimensional. Immunohistochemistry. Melanoma, Experimental. Mice. Mice, Nude. Mice, Transgenic. Microscopy, Electron, Transmission. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730031.001).
  • [ISSN] 0026-2862
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-Franse LV, Griffioen AW: Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett; 2007 Aug 28;254(1):128-36
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site.
  • In the present study we investigated lymphatic vessel density as well as the expression level of the lymphangiogenic factors VEGF-C and -D in a series of 121 ductal breast cancer tissues using immunohistochemical stainings.
  • We found that in the primary tumors the lymphatic vessel density, as well as the expression of both VEGF-C and -D, did not relate to grade, tumor stage, progression or patient survival.
  • Furthermore, in tumors in which lymphatic vessels were present, a Ki-67/podoplanin double staining indicated the absence of proliferating lymphatic endothelial cells.
  • In contrast, we did find a correlation between intratumoral lymphatic vessel density inside the lymph node metastases and patient survival.
  • Another parameter that revealed prognostic value was the presence of tumor cells within the lymphatic vessels.
  • Interestingly, expression of VEGF-D was found to be related to the presence of intralymphatic tumor cells.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymphangiogenesis. Lymphatic Vessels / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Lett. 2007 Oct 28;256(2):279-81; author reply 283-4 [17714860.001]
  • (PMID = 17442484.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


11. Tamura N, Tamura N: Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e11617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The multivariate analyses with an assessment of pathological effect of NAC, grading system for lymph vessel tumor emboli (LVTE), and histological factors of tumors in lymph nodes in addition to well-known prognostic clinicopathological factors were performed in IDC patients with nodal metastasis and in those of pTNM stage III as well as IDC patients as a whole.
  • Severe tumor stroma in nodal metastatic tumors significantly increased the HRs of tumor recurrence of IDC patients in the both group.
  • Number of mitotic figures in nodal metastatic tumors significantly increased the HRs of tumor death in IDC patients with nodal metastasis.
  • Tumor necrosis in primary-invasive-tumors was a significant factor for tumor recurrence of patients in the both.
  • CONCLUSIONS: The study clearly demonstrated that grading system for LVTE, and characteristics of nodal metastatic tumors as well as the presence of tumor necrosis in primary-invasive tumors are very important prognostic factors for IDC patients who received NAC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Shuang Y, Wang B, Wen S, Huang Y: [Clinical significance of lymph vessel density marked by D2-40 in laryngeal squamous cell carcinomas]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Feb;23(3):102-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of lymph vessel density marked by D2-40 in laryngeal squamous cell carcinomas].
  • OBJECTIVE: To study the relationship between lymphatic vessel density and clinicopathological features of laryngeal squamous cell carcinoma.
  • METHOD: The lymph vessels, 40 specimens of LSCC and normal mucosa, were quantitated by SABC immunohistochemistry staining with lymphatic endothelial marker oncofetal antigen M2A Monoclonal antibody (D2-40).
  • The density of peritumoral D2-40(+) vessels in the neck lymph nodal metastasis group was higher than that without neck lymph nodal metastasis group (P<0.05).
  • CONCLUSION: Tumor lymph vessel mainly means peritumoral lymph vessel.
  • The density of peritumoral lymph vessel marked with D2-40 in laryngeal carcinoma tissues was significantly correlated with progression and invasion of tumor.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Laryngeal Neoplasms / pathology. Lymphatic Vessels / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal. Carcinoembryonic Antigen / immunology. Female. Humans. Immunohistochemistry / methods. Lymph Nodes / pathology. Lymphangiogenesis. Lymphatic Metastasis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452724.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


13. Audet N, Beasley NJ, MacMillan C, Jackson DG, Gullane PJ, Kamel-Reid S: Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg; 2005 Dec;131(12):1065-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer.
  • OBJECTIVE: To examine the relationship between intratumoral lymphatic vessel density and clinical and pathological variables in patients with head and neck squamous cell carcinoma.
  • DESIGN: Archived paraffin-embedded biopsy specimens were sectioned and stained with hematoxylin-eosin and anti-LYVE-1 antibody, a highly specific marker for lymphatic endothelium.
  • Tumor grade, infiltrating margin, inflammatory infiltrate, and percentage of tumor necrosis were noted and lymphatic vessel density measured using Chalkley point counting.
  • INTERVENTIONS: Measurement of intratumoral lymphatic vessel density in pretreatment tissue biopsy specimen.
  • MAIN OUTCOME MEASURES: Disease-free and disease-specific survival, tumor occurrence, and nodal status.
  • RESULTS: In patients with laryngeal carcinoma there was a significant relationship between the presence of intratumoral lymphatics and nodal metastases at presentation (P = .02) and poorly differentiated tumor grade (P = .02).
  • Patients with high lymphatic vessel density also had a significantly worse disease-specific survival (P = .03).
  • CONCLUSIONS: In this patient sample, the development of intratumoral lymphatics in laryngeal carcinoma, but not in oropharyngeal or hypopharyngeal carcinoma, is associated with a spread of the tumor to regional lymph nodes.
  • Detecting tumor lymphatic vessel proliferation is another step in the understanding of tumor biology, and the targeting of lymphatic growth may be of potential therapeutic benefit in selected patients with head and neck squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Lymphatic Vessels / pathology
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Glycoproteins / metabolism. Humans. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Immunohistochemistry. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / pathology. Lymphatic Metastasis. Male. Middle Aged. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Prognosis. Survival Analysis. Vesicular Transport Proteins

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365219.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / LYVE1 protein, human; 0 / Vesicular Transport Proteins
  •  go-up   go-down


14. Saito H, Fukumoto Y, Osaki T, Yamada Y, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M: Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol; 2008 Feb 1;97(2):132-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer.
  • BACKGROUND AND OBJECTIVES: To determine the prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in gastric cancer patients.
  • RESULTS: The n ratio was significantly greater in cases with a large tumor, undifferentiated tumor, lymphatic vessel invasion, or blood vessel invasion.
  • Furthermore, the n ratio was significantly correlated with the depth of invasion, level of lymph node metastasis, and number of lymph node metastases.
  • The prognosis for gastric cancer patients correlated well with the n ratio.
  • Multivariate analysis indicated that the n ratio, but not the number of lymph node metastases, was an independent prognostic indicator.
  • Moreover, the n ratio was an independent prognostic factor in N1, N2, and N3 patients defined by the Japanese Classification of Gastric Cancer (JCGC).
  • CONCLUSIONS: The n ratio is useful for evaluating the status of lymph node metastasis in gastric cancer.
  • Therefore, the addition of the n ratio to the N (nodal) category defined by the JCGC may be a useful strategy in the N-staging classification of gastric cancer.
  • [MeSH-major] Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979134.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bilici A, Seker M, Ustaalioglu BB, Yilmaz B, Doventas A, Salepci T, Gumus M: Determining of metastatic lymph node ratio in patients who underwent D2 dissection for gastric cancer. Med Oncol; 2010 Sep;27(3):975-84
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining of metastatic lymph node ratio in patients who underwent D2 dissection for gastric cancer.
  • The purpose of this study was to determine outcome of the ratio of metastatic lymph nodes to the total number of dissected lymph nodes (MLR) in patients with gastric cancer.
  • We retrospectively analyzed 111 patients who underwent D(2) lymph node dissection.
  • The MLR was significantly higher in patients with a larger tumor, lymphatic vessel invasion, blood vessel invasion and perineural invasion, and advanced stage.
  • Moreover, the MLR was significantly associated with the depth of invasion and the number of lymph node metastasis.
  • The univariate analysis revealed for overall survival (OS) that stage of disease, lymphatic vessel invasion, blood vessel invasion, perineural invasion, lymph node metastasis (UICC/AJCC pN stage) and MLR were relevant prognostic indicators.
  • Our results indicated that MLR and UICC/AJCC pN staging system were important prognostic factors for OS of patients with D(2) lymph node dissection in gastric cancer in a multivariate analysis.
  • MLR may be useful for evaluating the status of lymph node metastasis in gastric cancer.
  • [MeSH-major] Carcinoma / surgery. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Algorithms. Disease-Free Survival. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Tumor Burden

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885750.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement